Breaking News Instant updates and real-time market news.

TOT

Total

$47.00

0.15 (0.32%)

, RDS.A

Royal Dutch Shell

$50.66

0.13 (0.26%)

10:45
11/22/16
11/22
10:45
11/22/16
10:45

OPEC oil cut hinges on agreements from Iraq and Iran, Reuters says

OPEC is in the midst of debating an oil output curtailment of 4%-4.5% for all members except Libya and Nigeria next week, says Reuters. The deal's advancement depends on agreements from Iraq and Iran, neither of which are certain to back the pact, added Reuters. Publicly traded companies in the space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Exxon Mobil (XOM), Royal Dutch Shell (RDS.A) and Total (TOT). Reference Link

TOT

Total

$47.00

0.15 (0.32%)

RDS.A

Royal Dutch Shell

$50.66

0.13 (0.26%)

BP

BP

$34.35

-0.05 (-0.15%)

XOM

Exxon Mobil

$86.56

0.07 (0.08%)

CVX

Chevron

$110.39

0.21 (0.19%)

COP

ConocoPhillips

$45.95

-0.41 (-0.88%)

  • 29

    Nov

  • 02

    Dec

  • 05

    Dec

TOT Total
$47.00

0.15 (0.32%)

09/08/16
BERN
09/08/16
DOWNGRADE
BERN
Market Perform
Total downgraded to Market Perform from Outperform at Bernstein
Bernstein analyst Oswald Clint, downgraded Total (TOT) based on his new analysis which shows that its upstream ROIC ranks fifth among the European integrated oil names he covers. The analyst says that Shell (RDS.A), BP (BP), and Eni (E) rank first, second, and third, respectively.He set a $56.61 price target on Total.
08/04/16
LEHM
08/04/16
UPGRADE
LEHM
Overweight
Total upgraded to Overweight from Equal Weight at Barclays
11/02/16
JPMS
11/02/16
DOWNGRADE
JPMS
Neutral
Total downgraded to Neutral from Overweight at JPMorgan
07/28/16
BERN
07/28/16
NO CHANGE
BERN
Total showing resiliency, says Bernstein
Bernstein analyst Oswald Clint says that Total's Q2 results showed that the company is benefiting from the resilience of its portfolio and its lack of significant exposure to the U.S. The analyst notes that the company's cash flow from operating activities has dropped only 23% in 1H16 despite a decline of more than 30% in brent prices.Clint says the comapny is on track to meet its targets, while it continues to have "a great portfolio." He reiterates an Outperform rating on the shares.
RDS.A Royal Dutch Shell
$50.66

0.13 (0.26%)

11/22/16
UBSW
11/22/16
INITIATION
UBSW
Buy
Royal Dutch Shell initiated with a Buy at UBS
11/22/16
11/22/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Royal Dutch Shell (RDS.A) initiated with a Buy at UBS. 2. Acushnet Holdings (GOLF) initiated with a Buy at UBS, a Hold at Deutsche Bank, a Market Perform at Wells Fargo, a Buy at SunTrust, an Overweight at KeyBanc, a Buy at Nomura, a Neutral at JPMorgan, a Buy at Jefferies, an Outperform at Raymond James, a Neutral at Credit Suisse, and an Overweight at Morgan Stanley. 3. BlackLine (BL) initiated with a Neutral at Goldman, an Outperform at Baird, a Neutral at JPMorgan, an Overweight at Pacific Crest, an Outperform at Raymond James, and an Outperform at William Blair. 4. Quantenna Communications (QNTA) initiated with a Buy at Deutsche Bank, an Overweight at Barclays, an Outperform at William Blair, a Buy at Needham, a Buy at Roth Capital, and an Overweight at Morgan Stanley. 5. Chubb (CB) initiated with a Buy at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/02/16
JPMS
11/02/16
UPGRADE
JPMS
Overweight
Royal Dutch Shell upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Christyan Malek upgraded Royal Dutch Shell to Overweight.
10/14/16
10/14/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Royal Dutch Shell (RDS.A, RDS.B) downgraded to Sell from Hold at Canaccord with the firm citing the gap between the average free cash flow generation of Shell over the past two decades and the medium-term target. 2. bluebird bio (BLUE) downgraded to Sell from Hold at Cantor with analyst Elemer Piros saying he sees a lack of catalysts as he does not expect data to be announced at this year's American Society of Hematology conference to de-risk the hemoglobinopathy programs. 3. Fluor (FLR) downgraded to Neutral from Accumulate at Seaport Global with analyst Ryan Cassil citing persistently weaker global macroeconomic trends and expectations for a continuation of weaker project activity in 2017. 4. Boston Beer (SAM) downgraded to Hold from Buy at Berenberg. 5. Estee Lauder (EL) downgraded to Neutral from Overweight at Piper Jaffray after the firm's semi-annual proprietary "Taking Stock With Teens" survey. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BP BP
$34.35

-0.05 (-0.15%)

11/15/16
11/15/16
DOWNGRADE
Target $37

Outperform
BP downgraded to Outperform at CLSA
As previously reported, CLSA downgraded BP to Outperform and lowered its price target to $37 from $40. Analyst Asit Sen said BP has done a remarkable job positioning for long-term growth but awaits on visibility into its lower 48 strategy where bolt-on acquisitions make more sense.
11/15/16
11/15/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. FedEx (FDX) downgraded to Hold from Buy at Stifel with analyst David Ross citing valuation, as well as concerns about the "still-fragile global economic environment" and the integration of its TNT acquisition. 2. Abercrombie & Fitch (ANF) downgraded to Underperform at FBR Capital while the firm also downgraded American Eagle (AEO) to Market Perform from Outperform. 3. Amplify Snack Brands (BETR) downgraded to Perform from Outperform at Oppenheimer and to Neutral from Outperform at Credit Suisse. 4. BP (BP) downgraded to Outperform from Buy at CLSA while the firm also downgraded ConocoPhillips (COP) to Underperform from Outperform. 5. Cheesecake Factory (CAKE) downgraded to Hold from Buy at Maxim with analyst Stephen Anderson saying he sees the company's above-peer comps, market share gains, and solid new unit development prospects as being priced in after the 22% jump in the stock from its late October low. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/15/16
LYON
11/15/16
DOWNGRADE
Target $37
LYON
Outperform
BP downgraded to Outperform from Buy at CLSA
11/02/16
11/02/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Hold from Buy at Argus and to Market Perform from Outperform at BMO Capital. 2. BP (BP) downgraded to Hold from Buy at Societe Generale. 3. Corning (GLW) downgraded to Buy from Conviction Buy at Goldman with analyst Doug Clark saying the restocking phase of glass/TV cyclical recovery is now "well understood and largely behind us." 4. Adeptus Health (ADPT) downgraded to Underperform from Buy at BofA/Merrill, to Hold from Buy at Jefferies, and to Equal Weight from Overweight at Stephens. 5. Brookdale Senior Living (BKD) downgraded to Underperform from Neutral at BofA/Merrill, to Market Perform from Outperform at Wells Fargo, and to Outperform from Top Pick at RBC Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
XOM Exxon Mobil
$86.56

0.07 (0.08%)

11/07/16
BERN
11/07/16
NO CHANGE
BERN
InterOil Exxon deal still likely to close despite court loss, says Bernstein
After an appeals court overturned a lower court's approval of InterOil's (IOC) deal with Exxon (XOM), Bernstein analyst Neil Beveridge says that the ruling "was largely related to procedural issues." He thinks that the deal will close in late 1Q17 despite the court's ruling. However, he keeps a Market Perform rating on InterOil.
10/31/16
10/31/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Nike (NKE) downgraded to Underperform from Neutral at BofA/Merrill with analyst Robert Ohmes citing share loss and lack of innovation. 2. AbbVie (ABBV) downgraded to Neutral from Outperform at Credit Suisse with analyst Vamil Divan saying he is increasingly concerned about Humira's longevity given the more challenging payer environment and increasing calls for further pricing transparency. 3. Home Depot (HD) and Lowe's (LOW) downgraded to Neutral from Overweight at Piper Jaffray. 4. Exxon Mobil (XOM) downgraded to Neutral from Conviction Buy at Goldman with analyst Neil Mehta citing a lack of catalysts to drive the stock higher. 5. AutoNation (AN) downgraded to Neutral from Buy at BofA/Merrill with analyst John Murphy saying the company's business transformation announcement appears to be risky and will result in excessive costs, management distraction, and diverts capital from share repurchases and acquisitions. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/31/16
GSCO
10/31/16
UPGRADE
Target $118
GSCO
Conviction Buy
Chevron upgraded to Conviction Buy from Neutral at Goldman
Goldman Sachs analyst Neil Mehta upgraded Chevron (CVX) to Conviction Buy from Neutral saying that after a decade of relatively flat production, the company is positioned for "strong volume improvement." The analyst also expects "robust" free cash flow improvement, which he thinks will more than cover the dividend yield of 4.2%. Mehta raised his price target for Chevron shares to $118 from $108. The analyst coupled the upgrade with a downgrade of Exxon Mobil (XOM) to Neutral.
10/31/16
GSCO
10/31/16
DOWNGRADE
Target $93
GSCO
Neutral
Exxon Mobil downgraded to Neutral from Conviction Buy at Goldman
Goldman Sachs analyst Neil Mehta downgraded Exxon Mobil (XOM) to Neutral from Conviction Buy citing a lack of catalysts to drive the stock higher. The analyst sees a more favorable risk/reward in shares of Chevron (CVX), a stock he upgraded this morning to Conviction Buy. Mehta lowered his price target for Exxon shares to $93 from $98. The shares closed Friday down $2.14 to $84.78 following the company's Q3 results.
CVX Chevron
$110.39

0.21 (0.19%)

11/21/16
OPCO
11/21/16
NO CHANGE
OPCO
Oppenheimer recommends buying Technology, Energy ahead of breakout
Oppenheimer analyst Ari Wald says that the S&P 500's bullish reversal of its eight-week downtrend is confirming the start of a year-end rally, and cyclical stocks should be owned given resuming strength in the index's long-term trend. The analyst thinks the current opportunity is to buy Technology and Energy ahead of a breakout, namely Apple (AAPL), Seagate (STX), Skyworks (SWKS), Western Digital (WDC), Apache (APA), Chevron (CVX), Halliburton (HAL), and Helmerich & Payne (HP).
11/15/16
11/15/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Fortinet (FTNT) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Melissa Gorham saying she is more constructive on Fortinet heading into fiscal 2017 given the stable demand environment, free cash flow generation, easier comps, and more durable renewals. 2. Advance Auto Parts (AAP) upgraded to Strong Buy from Outperform at Raymond James and to Positive from Neutral at Susquehanna following the company's quarterly report. 3. Chevron (CVX) upgraded to Buy from Outperform at CLSA while the firm also upgraded EOG Resources (EOG) to Outperform from Underperform. 4. Harley-Davidson (HOG) upgraded to Sector Perform from Underperform at RBC Capital with analyst Joseph Spak saying that risks to the company's growth have dissipated, partly due to the potential of President-elect Trump's policies to spark increased consumer spending. 5. Cheesecake Factory (CAKE) upgraded to Buy from Hold at Argus with analyst John Staszak saying investors should be attracted to Cheesecake by its dividend hikes, share repurchases, and ability to open new stores while generating consistent comparable sales growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/15/16
LYON
11/15/16
UPGRADE
Target $127
LYON
Buy
Chevron upgraded to Buy on short-cycle emphasis at CLSA
As previously reported, CLSA upgraded Chevron to Outperform and increased its price target to $127 from $118. Analyst Asit Sen said Chevron's strategic shift towards its short-cycle business is a "game changer" He believes the Permian Q3 update was just the beginning and expects short-cycle to be +15% of total 2020 production.
11/15/16
LYON
11/15/16
UPGRADE
LYON
Buy
Chevron upgraded to Buy from Outperform at CLSA
COP ConocoPhillips
$45.95

-0.41 (-0.88%)

11/15/16
LYON
11/15/16
DOWNGRADE
LYON
Underperform
ConocoPhillips downgraded to Underperform from Outperform at CLSA
11/15/16
LYON
11/15/16
DOWNGRADE
Target $47
LYON
Underperform
ConocoPhillips downgraded to Underperform at CLSA
As previously reported, CLSA downgraded ConocoPhillips to Underperform and maintained its $47 price target. Analyst Asit Sen said ConocoPhillips' lack of Delaware/Midland exposure is a significant negative when compared to peers and prefers more aggressive moves to lower debt instead of the $3B announced buyback.
11/07/16
EDJN
11/07/16
UPGRADE
EDJN
Buy
ConocoPhillips upgraded to Buy from Hold at Edward Jones

TODAY'S FREE FLY STORIES

SCSS

Select Comfort

$22.96

0.64 (2.87%)

07:07
12/06/16
12/06
07:07
12/06/16
07:07
Downgrade
Select Comfort rating change  »

Select Comfort downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIK

Michaels

$24.31

0.34 (1.42%)

07:07
12/06/16
12/06
07:07
12/06/16
07:07
Hot Stocks
Michaels announces increase of share repurchase program by $300M »

In December 2016, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PFG

Principal Financial

$59.47

1.69 (2.92%)

07:06
12/06/16
12/06
07:06
12/06/16
07:06
Conference/Events
Principal Financial to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SPPI

Spectrum

$4.03

0.03 (0.75%)

07:06
12/06/16
12/06
07:06
12/06/16
07:06
Hot Stocks
Spectrum highlights survival advantage in case match control analysis of PROPEL »

Spectrum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 11

    Dec

PLUG

Plug Power

$1.47

0.04 (2.80%)

07:06
12/06/16
12/06
07:06
12/06/16
07:06
Initiation
Plug Power initiated  »

Plug Power initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

PSTI

Pluristem

$1.55

0.08 (5.44%)

07:06
12/06/16
12/06
07:06
12/06/16
07:06
Hot Stocks
Pluristem PLX-R18 advances into second cohort of study for ARS »

Pluristem Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPP

Green Plains Partners

$17.85

-0.15 (-0.83%)

07:06
12/06/16
12/06
07:06
12/06/16
07:06
Upgrade
Green Plains Partners rating change  »

Green Plains Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$25.82

-0.07 (-0.27%)

07:05
12/06/16
12/06
07:05
12/06/16
07:05
Hot Stocks
AstraZeneca says data presented shows TAGRISSO superiority over chemotherapy »

AstraZeneca presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 16

    Feb

EARS

Auris Medical

07:05
12/06/16
12/06
07:05
12/06/16
07:05
Hot Stocks
Auris Medical on track to resume enrollment of Keyzilen Phase 3 trial »

Auris Medical Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$49.00

1.81 (3.84%)

, IL

Intralinks

$11.27

0.11 (0.99%)

07:04
12/06/16
12/06
07:04
12/06/16
07:04
Earnings
Synchronoss sees FY17 pro forma EPS $2.45-$2.60 for combined entity »

May not compare to…

SNCR

Synchronoss

$49.00

1.81 (3.84%)

IL

Intralinks

$11.27

0.11 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

CHTR

Charter

$270.93

4.26 (1.60%)

07:04
12/06/16
12/06
07:04
12/06/16
07:04
Initiation
Charter initiated  »

Charter initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MDGN

Medgenics

07:04
12/06/16
12/06
07:04
12/06/16
07:04
Initiation
Medgenics initiated  »

Medgenics initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AM

Antero Midstream

$28.48

-0.1 (-0.35%)

07:04
12/06/16
12/06
07:04
12/06/16
07:04
Upgrade
Antero Midstream rating change  »

Antero Midstream upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSBC

HSBC

$39.86

0.17 (0.43%)

07:03
12/06/16
12/06
07:03
12/06/16
07:03
Upgrade
HSBC rating change  »

HSBC upgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGTX

TG Therapeutics

$5.70

0.2 (3.64%)

07:03
12/06/16
12/06
07:03
12/06/16
07:03
Hot Stocks
TG Therapeutics GENUINE Phase 3 study reaches target enrollment »

TG Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$49.00

1.81 (3.84%)

07:03
12/06/16
12/06
07:03
12/06/16
07:03
Hot Stocks
Synchronoss to divest part of activation business to Sequential for $146M »

Synchronoss is also…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

SNCR

Synchronoss

$49.00

1.81 (3.84%)

, IL

Intralinks

$11.27

0.11 (0.99%)

07:03
12/06/16
12/06
07:03
12/06/16
07:03
Hot Stocks
Synchronoss to acquire Intralinks for $13/share, or $821M in equity value »

Synchronoss Technologies…

SNCR

Synchronoss

$49.00

1.81 (3.84%)

IL

Intralinks

$11.27

0.11 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

TEVA

Teva

$37.04

0.51 (1.40%)

07:02
12/06/16
12/06
07:02
12/06/16
07:02
Recommendations
Teva analyst commentary  »

Wells views departure of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Apr

NVCN

Neovasc

$1.42

0.56 (65.12%)

07:02
12/06/16
12/06
07:02
12/06/16
07:02
Hot Stocks
Neovasc provides update on Tiara transcatheter mitral valve »

Neovasc provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDS

GDS Holdings

$9.93

-0.07 (-0.70%)

07:02
12/06/16
12/06
07:02
12/06/16
07:02
Initiation
GDS Holdings initiated  »

GDS Holdings initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$49.00

1.81 (3.84%)

, IL

Intralinks

$11.27

0.11 (0.99%)

07:02
12/06/16
12/06
07:02
12/06/16
07:02
Hot Stocks
Breaking Hot Stocks news story on Synchronoss, Intralinks »

Synchronoss to acquire…

SNCR

Synchronoss

$49.00

1.81 (3.84%)

IL

Intralinks

$11.27

0.11 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

KKR

KKR

$15.67

0.19 (1.23%)

, BX

Blackstone

$26.40

0.54 (2.09%)

07:01
12/06/16
12/06
07:01
12/06/16
07:01
Hot Stocks
KKR to acquire Optiv Security from investors, including fund managed by Blackstone »

Optiv Security, a…

KKR

KKR

$15.67

0.19 (1.23%)

BX

Blackstone

$26.40

0.54 (2.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

AZO

AutoZone

$776.42

-7.32 (-0.93%)

07:00
12/06/16
12/06
07:00
12/06/16
07:00
Earnings
AutoZone reports Q1 EPS $9.36, consensus $9.31 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 14

    Dec

ROP

Roper Technologies

$181.64

-0.68 (-0.37%)

, PROJ

Deltek

06:59
12/06/16
12/06
06:59
12/06/16
06:59
Hot Stocks
Roper Technologies to buy Deltek in all cash transaction valued at $2.8B »

Roper Technologies (ROP)…

ROP

Roper Technologies

$181.64

-0.68 (-0.37%)

PROJ

Deltek

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$228.55

5.19 (2.32%)

06:59
12/06/16
12/06
06:59
12/06/16
06:59
Periodicals
Goldman Sachs leads financing round in Canadian startup Hubba, WSJ says »

Goldman Sachs led a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.